Along with WHO, Mologic, and Leiden University Medical Center, FIND is developing two rapid diagnostic tests to detect circulating anodic antigen in blood or urine.
During the year, the growing threat of antimicrobial resistance drove development and adoption of advanced diagnostic tests, including molecular testing.
Backed by the UK and Swiss governments, FIND's Diagnostics Use Accelerator will support studies that could lead to improved use of antibiotics, as well as new diagnostics.
Developers claim the immunochromatographic assay has advantages over other tests on the market for diagnosing TB in HIV patients, as well as the conventional approach.
The firm has been placing point-of-care systems primarily in the private sector, but may have increased access once it completes WHO prequalification review.
FIND will lead evaluation studies in Cameroon and Georgia between September 2018 and May 2019 to confirm the assay's diagnostic accuracy and commercial utility.
